Abetimus sodium: a medication for the prevention of lupus nephritis flares

Bibliography

• Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham England. Relationship to ethnicity and country of birth. Arthritis Rheum 1995;38(4):551-8
   PubMed Web of Science ®Google Scholar
• Bargman JM. How did Cyclophosphamide become the drug of choice for Lupus Nephritis? Nephrol Dial Transplant 2009;24(2):381-4
   PubMed Web of Science ®Google Scholar
• Mok CC, Ying KY, Ng WL, et al. Long-trerm outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006;119(4):355.e25-33
   PubMed Web of Science ®Google Scholar
• Mosca M, Baldini C, Bombardieri S. LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus. Expert Opin Pharmacother 2007;8(6):873-9
   PubMed Web of Science ®Google Scholar
• Furie R. Abetimus (Riquent) for the prevention of nephritic flares in patients with systemic lupus erythematosus. Rheum Dis Clin North Am 2006;32(1):149-56
   PubMed Web of Science ®Google Scholar
• Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358(9):929-39
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Shoenfeld Y, Walport M, et al. Detection of cross-reactive anti-DNA antibody idiotypes in the serum of systemic lupus erythematosus patients and of their relatives. Arthritis Rheum 1985;28(9):999-1007
   PubMed Web of Science ®Google Scholar
• Koffler D, Schur PH, Kunkel HG. Immunological studies concerning the nephritis of systemic lupus erythematosus. J Exp Med 1967;126(4):607-24
   PubMed Web of Science ®Google Scholar
• Winfield JB, Faiferman I, Koffler D. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus; association of high avidity antinative DNA antibody with glomerulonephritis. J Clin Invest 1977;59:90-6
   PubMed Web of Science ®Google Scholar
• ter Borg EJ, Horst G, Hummel EJ, et al. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990;33(5):634-43
   PubMed Web of Science ®Google Scholar
• Linnik MD, Hu JZ, Heilbrunn KR, et al. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum 2005;52(4):1129-37
   PubMed Web of Science ®Google Scholar
• Hahn BH. Antibodies to DNA. N Engl J Med 1998;338:1359-68
   PubMed Web of Science ®Google Scholar
• Jones DS, Barstad PA, Feild MJ, et al. Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis. J Med Chem 1995;38:2138-44
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Tumlin JA. LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus. Lupus 2004;13(5):323-7
   PubMed Web of Science ®Google Scholar
• Weisman MH, Bluestein HG, Berner CM, de Haan HA. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol 1997;24(2):314-8
   PubMed Web of Science ®Google Scholar
• Coutts SM, Plunkett ML, Iverson GM, et al. Pharmacological intervention in antibody mediated disease. Lupus 1996;5(2):158-9
   PubMed Web of Science ®Google Scholar
• Hepburn B, Furie R, Cash J, et al. Reduction of anti-dsDNA antibodies using LJP-394 in patients with lupus. Arthritis Rheum 1996;39:S307
   Google Scholar
• Furie RA, Cash JM, Cronin ME, et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 2001;28(2):257-65
   PubMed Web of Science ®Google Scholar
• Hartley SB, Cooke MP, Fulcher DA, et al. Elimination of self-reactive B-lymphocytes proceeds in two stages: arrested development and cell death. Cell 1993;72(3):325-35
   PubMed Web of Science ®Google Scholar
• Linnik MD, O'Rourke AM, Crowther MA. Pharmacokinetics of high dose abetimus sodium in normal subjects with specific assessment of effect on coagulation. J Clin Pharmacol 2008;48:909-18
   PubMed Web of Science ®Google Scholar
• Linnik M, Staines NA, Berden J, Isenberg DA. Workshop report on some new ideas about the treatment of systemic lupus erythematosus. Lupus 2002;11:793-6
   PubMed Web of Science ®Google Scholar
• Alarcón-Segovia D, Tumlin JA, Furie RA, et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003;48(2):442-54
   PubMed Web of Science ®Google Scholar
• Cardiel MH, Tumlin JA, Furie RA, et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum 2008;58(8):2470-80
   PubMed Web of Science ®Google Scholar
• Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 1991;34(8):937-44
   PubMed Web of Science ®Google Scholar
• Linnik MD, Tansey MJ, Joh T. Dose Dependent Reduction in Anti-dsDNA Antibody Levels Observed With Abetimus Sodium Through 52 Weeks in the Phase 3 ASPEN Study (Abetimus Sodium in Patients With a History of Lupus Nephritis). Presented at the 2008 ACR Meeting in San Francisco, CA
   Google Scholar
• La Jolla Pharmaceutical Company (2008-12-08). La Jolla pharmaceutical provides update on its auction rate securities and its ongoing Riquent® phase 3 ‘ASPEN’ lupus trial. Press Release. Available from: http://www.ljpc.com/pressrelease/121808.htm Retrieved on 2008-12-30
   Google Scholar
• BioMarin Pharmaceuticals (2009-2-12). Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile. Press Release. Available from: http://phx.corporate-ir.net/phoenix.zhtml? c = 106657&p = RssLanding&cat = news&id = 1255856 Retrieved on 2009-2-22
   Google Scholar